PP353

About Persica Pharmaceuticals

Persica Pharmaceuticals is pioneering a novel, non-opioid treatment for chronic low back pain (cLBP) driven by Modic changes, which are believed to be caused by a bacterial infection in vertebral discs. Its lead asset, PP353, is a patented, targeted intradiscal antibiotic injection designed to deliver high local drug concentration with a single administration, minimizing systemic side effects. The company is led by an experienced team with strong track records in drug development and biotech financing, and it has published promising efficacy data for PP353 in a peer-reviewed journal. Persica is targeting a significant unmet need in a large, identifiable patient population with limited effective treatment options.

Therapeutic Areas